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Table 1. Effect of Anti c-Kit mAb on Peripheral Blood Cell Counts
Day 0
Control Day 2 Day 4 Day 7 Day 11
WBC 12.1 6.6 4.2 2.6 9.5
Hgb 15.1 14.5 13.2 6.2 5.3
ANC 796 180 32 26 320
Platelet Count 1107 1182 1098 763 220
Mice injected with 1 mg ACK-2 intravenously on Days 0, 2 & 4.
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EPITHELIAL CHIMERISM IN THE ORAL MUCOSA AFTER HUMAN HEMA-
TOPOIETIC CELL TRANSPLANTATION
Spyridonidis, A., Zeiser, R., Metaxas, Y., Faber, P., Finke, J. Freiburg
University Medical Center, Freiburg, Germany.
Several study groups have reported on a nonhematopoietic chi-
merism following allogeneic hematopoietic cell transplantation
(aHCT) both in animals and humans. We recently investigated this
phenomenon in humans and described the pitfalls of identiﬁcation
of epithelial chimerism (Spyridonidis et al, Am J Pathol 164:1147–
1155, 2004). The purpose of the present study was to examine
epithelial chimerism in single cells isolated from the oral mucosa.
Buccal scrapings obtained from 13 female patients who underwent
a sex-mismatched aHCT were employed to prepare cytospins. The
examination was performed 75–1964 days after aHSCT. At this
time point, no patient had signs of mucositis or oral GvHD.
Cytospin preparations were examined with a combination of FISH
for the Y or the XY chromosome; immunoﬂuorescent stain for the
epithelial-speciﬁc marker cytokeratin (CK), for CD45, and Drag
cell nuclei stain; with APAAP immunocytochemistry using either
CD15-, CD45-, CD68-, or CD3-speciﬁc antibodies; and with
hematoxylin and eosin (HE) staining. Evaluation of epithelial chi-
merism was performed with laser scanning confocal microscopy
from examiners who were not aware of the patients’ present or past
medical history. CD45 or CD3 cells were found in 4 patients
with a frequency of  1%. No CD68 or CD15 positive mac-
rophages were detected. In the FISH-Y combined stains, we de-
tected Y/CK/CD45 cells in 12 of 13 patients (92%), with a
mean of 1.8% Y/CK/CD45 cells per 200 total cells analyzed
(range, 0.5%-7.3%). The identiﬁed Y/CK/CD45 cells were
counterstained with HE and revealed an epithelial morphology.
Screening of 5 patients with XY stain demonstrated all Y cells of
them having only 1 X chromosome, making fusion as the under-
lying mechanism unlikely. We retrospectively reviewed the trans-
plantation documents of every patient and found a signiﬁcant
correlation (P value  .0028) between the severity of mucositis in
the early posttransplantation period (up to day 30) and the
degree of epithelial chimerism found at later time points (days
75- 1964), where no signs of mucositis were present. We
conclude that epithelial chimerism of the oral mucosa is a real
phenomenon after aHSCT. Further molecular investigation on a
single-nucleus level and analysis of greater number of transplanted
patients are needed to understand the underlying mechanisms
responsible for generation of the donor derived epithelial cells.
Tissue injury seems to play a role in these mechanisms.
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PEGFILGRASTIM VERSUS FILGRASTIM TO ACCELERATE HEMATOPOI-
ETIC RECOVERY AFTER HIGH-DOSE MELPHALAN AND AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) FOR MULTI-
PLE MYELOMA
Olin, R.L., Luger, S.M., Porter, D.L., Schuster, S.J., Tsai, D.,
Nasta, S., Perl, A., Loren, A.W., Goldstein, S., Mangan, P., Sherry, V.,
Cunningham, K., Sachs, B., Hummel, K., Stadtmauer, E.A. Bone
Marrow and Stem Cell Transplant Program, University of Pennsylva-
nia, Philadelphia, PA.
High-dose melphalan followed by ASCT is a common compo-
nent of the early treatment for multiple myeloma. Daily subcuta-
neous injections of ﬁlgrastim (Neupogen) at 5 g/kg/day until
ANC  500/L are routinely administered at our center from day
4 following ASCT, to accelerate hematopoietic recovery and
lessen neutropenic complications. Pegﬁlgrastim (Neulasta) as a
single 6-mg ﬁxed dose via subcutaneous injection has been shown
to have similar efﬁcacy and ease of use as ﬁlgrastim in the non-
transplantation setting, but little data are available in the transplan-
tation setting. We began using pegﬁlgrastim on day 1 following
ASCT for patients with multiple myeloma and performed a retro-
spective cohort study comparing those who received ﬁlgrastim (the
ﬁlgrastim group [FG]; n  6) with those who received pegﬁlgras-
tim (the pegﬁlgrastim group [PG]; n  11). Transplantations
occurred between July 2002 and January 2004 and included all
patients transplanted for myeloma in that period for whom sufﬁ-
cient data were available. All patients had peripheral stem cells
harvested after cytoxan/ﬁlgrastim mobilization. Main outcome
measures were days from stem cell infusion to WBC nadir, days to
ANC  500/L, and days to ANC  1000/L. Subjects were
excluded if CBCs were drawn less often than every 4 days. There
were no signiﬁcant differences between the FG and the PG with
respect to the following variables: age, gender, hemoglobin, creat-
inine, calcium, albumin, beta-2 microglobulin, number of prior
lines of therapy, and number of CD34 cells infused. After trans-
plantation, the median number of days to WBC nadir was 7 (range,
5–9) in the FG and 6 (range, 5–8) in the PG (P  .31). However,
median number of days to ANC 500/L was 11.5 (range, 11–17)
in the FG and 10 (range, 9–12) for the PG (P  .02). Similarly,
median number of days to ANC  1000/L was 12 (range, 11–17)
for the FG and 11 (range, 10–13) for the PG (P  .03). Five of 6
patients in the FG had neutropenic fever after transplantation,
compared with 5 of 11 patients in the PG (P  .30). Currently, no
signiﬁcant differences in infection or relapse rates between the
groups was noted, and there were no deaths in either group. In this
retrospective cohort study, pegﬁlgrastim was safe and at least
equivalent to ﬁlgrastim for accelerating hematopoiesis after ASCT
for multiple myeloma. Furthermore, there was no signiﬁcant dif-
ference in the incidence of neutropenic fever, infection, and sur-
vival, suggesting a similar clinical utility.
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VANGANCICLOVIR PROPHYLAXIS FOR THE PREVENTION OF CYTO-
MEGALOVIRUS REACTIVATION AND DISEASE IN ALLOGENEIC STEM
CELL TRANSPLANTATION RECIPIENTS
Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H.,
Gingrich, R. University of Iowa, Iowa City, IA.
Background: CMV infection continues to be an important cause
of morbidity and mortality after allogeneic stem cell transplanta-
tion. Valganciclovir (VGC), the valine ester of ganciclovir, has
excellent oral bioavailability and has the potential to replace intra-
venous ganciclovir in many situations, namely CMV prophylaxis or
preemptive therapy after allogeneic transplantation. Methods:
From October 2002 to April 2004, 34 patients who were either
CMV seropositive or had a seropositive donor were enrolled in
prospective trial of intravenous (IV) ganciclovir at 5 mg/kg twice a
day for 1 week, followed by oral VGC 900 mg twice a day for a
total of 180 days. IV ganciclovir was started at time of engraftment.
Dose adjustments of VCG were made according to renal function,
and growth factors were allowed in the event of neutropenia. Study
endpoints included incidence of CMV reactivation and disease
during the ﬁrst 180 days after transplantation. For the study,
viremia was deﬁned as a positive CMV blood culture by shell vial
or conventional culture. A positive antigenemia assay in patients
with severe (grade III-IV) GVHD was deﬁned as 1 positive cell on
either of 2 duplicate slides. For patients with no or mild GVHD
(grade I-II), a positive antigenemia assay was deﬁned as 2 positive
cells/slide. Results: Thirty-four patients were enrolled. Thirteen
patients were not able to proceed after consenting due to positive
antigenemia prior to starting study (3 patients), ﬁnancial reasons (3
patients), severe gut GVHD unabling oral intake (5 patients), or
death (2 patients). Of those who received VGC, the median age
Poster Session II
87BB&MT
